---
title: "Understanding the Market | JW THERAP-B rose over 10% as reports suggest its CAR-T drug is expected to enter the commercial insurance catalog"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/263927455.md"
description: "JW THERAP-B rose over 10%, as of the time of writing, it increased by 9.77%, priced at HKD 3.82, with a transaction volume of HKD 4.6331 million. According to a report by Yicai, on November 2, it was learned that JW THERAP's CAR-T cell drug, Rukiyolunase injection, is making smooth progress in negotiations to enter the commercial health insurance innovative drug catalog, with hopes of being included in the catalog, reducing the medication burden for patients and benefiting more patients. This is the first domestically approved Class 1 CAR-T in China, with a post-listing price of 1.29 million yuan per injection. On October 30, JW THERAP announced the signing of a strategic cooperation supplementary agreement with Regeneron Pharmaceuticals. This revision not only marks an important upgrade in the long-term cooperative relationship between the two parties but also opens a new phase of collaboration in TCR-T cell therapy and platform technology innovation. Through this supplementary agreement, JW THERAP will receive payments of up to USD 50 million, including milestone payments for MAGE-A4 product development, drug production process supervision milestone payments, option exercise fees, and milestone payments for lentiviral vector manufacturing processes"
datetime: "2025-11-03T01:49:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263927455.md)
  - [en](https://longbridge.com/en/news/263927455.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263927455.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/263927455.md) | [English](https://longbridge.com/en/news/263927455.md)


# Understanding the Market | JW THERAP-B rose over 10% as reports suggest its CAR-T drug is expected to enter the commercial insurance catalog

According to Zhitong Finance APP, JW THERAP-B (02126) rose over 10%, and as of the time of writing, it is up 9.77%, priced at HKD 3.82, with a transaction volume of HKD 4.6331 million.

In terms of news, according to Yicai, on November 2, it was reported that JW THERAP's CAR-T cell drug, Rukiyolun Injection, is making smooth progress in negotiations to be included in the commercial health insurance innovative drug directory, which is expected to reduce the medication burden on patients and benefit more patients. This is the first domestically approved Class 1 CAR-T in China, with a post-listing price of 1.29 million yuan per injection.

On October 30, JW THERAP announced the signing of a supplementary strategic cooperation agreement with Regeneron Pharmaceuticals. This revision not only marks an important upgrade in the long-term cooperative relationship between the two parties but also opens a new phase of collaboration in TCR-T cell therapy and platform technology innovation. Through this supplementary agreement, JW THERAP will receive payments of up to USD 50 million, including milestone payments for MAGE-A4 product development, drug production process supervision, option exercise fees, and milestone payments for lentiviral vector manufacturing processes

### 相關股票

- [JW THERAP-B (02126.HK)](https://longbridge.com/zh-HK/quote/02126.HK.md)

## 相關資訊與研究

- [Fosun Pharmaceutical's Subsidiary Gets Nod for Phase I Trial for Breast Cancer Drug](https://longbridge.com/zh-HK/news/281480931.md)
- [14:37 ETLevrx and Waltz Health Partner to Expand Access to Transparent Pharmacy Pricing](https://longbridge.com/zh-HK/news/281411704.md)
- [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/zh-HK/news/281501537.md)
- [BrYet US, Inc. to Present ML-016 Preclinical Efficacy Data at AACR 2026](https://longbridge.com/zh-HK/news/281647557.md)
- [Anixa CEO cites positive Phase 1 data for breast cancer vaccine, ovarian CAR-T in interview](https://longbridge.com/zh-HK/news/281763571.md)